Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 1:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 13,425 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Endocrine Disorder Clear all
Terminated Phase 3 Interventional

Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes

NCT00322257
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
inhaled human insulin, insulin detemir, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
86
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Concord, California + 78 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 19, 2026, 1:10 PM EDT
Recruiting Phase 1 Interventional

IDOV-Immune for Advanced Solid Tumors

NCT06910657
View directory record Official record
Conditions
Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Breast Cancer, Sarcoma, Bladder Cancer, Lung Cancer, Prostate Cancer, Cervical Cancers, Head and Neck Cancers, Adrenal Gland Tumors
Interventions
IDOV-Immune (oncolytic vaccinia virus)
Biological
Lead sponsor
ViroMissile, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
St Louis, Missouri • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 19, 2026, 1:10 PM EDT
Completed Phase 1 Interventional Results available

Effect of Prebiotics on the Gut Microbiome Profile and Beta Cell Function

NCT04114357
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Acetylated and Butyrylated High Amylose Maize Starch
Drug
Lead sponsor
Indiana University
Other
Eligibility
11 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 19, 2026, 1:10 PM EDT
Withdrawn Phase 3 Interventional

Mifepristone in Children With Refractory Cushing's Disease

NCT01925092
View directory record Official record
Conditions
Cushing's Disease
Interventions
mifepristone
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
6 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 4, 2014 · Synced Oct 19, 2026, 1:10 PM EDT
Completed Phase 2 Interventional Results available

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT01666444
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
pegylated liposomal doxorubicin (PLD), VTX-2337, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older · Female only
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
136
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Burbank, California + 104 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 19, 2026, 1:10 PM EDT
Terminated Not applicable Interventional Results available

The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors

NCT03641287
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Adenocarcinoma, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Malignant Ovarian Brenner Tumor, Ovarian Adenocarcinoma, Ovarian Carcinosarcoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Transitional Cell Carcinoma
Interventions
Exercise Counseling, Aerobic Exercise, Physiological Support, Quality-of-Life Assessment, Questionnaire Administration, Best Practice
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 19, 2026, 1:10 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

NCT05787587
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Extensive Stage Small Cell Lung Cancer (ES-SCLC), NSCLC
Interventions
IDE-161, Pembrolizumab
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
27
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 19, 2026, 1:10 PM EDT
Terminated Phase 1 Interventional Results available

Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer

NCT02047500
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
TH-302, Nab-paclitaxel, Gemcitabine
Drug
Lead sponsor
ImmunoGenesis
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Scottsdale, Arizona • Boston, Massachusetts • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Oct 19, 2026, 1:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identifying Genes That May Increase the Risk for Heart Disease in African Americans

NCT00344136
View directory record Official record
Conditions
Heart Diseases
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years to 95 Years
Enrollment
5,302 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2004
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jul 29, 2016 · Synced Oct 19, 2026, 1:10 PM EDT
Recruiting No phase listed Observational

Safety and Efficacy of Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA) in the Treatment of Pancreatic Lesions

NCT07737171
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA)
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
60 participants
Timeline
2026 – 2033
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 19, 2026, 1:10 PM EDT
Completed Phase 3 Interventional Results available

Time to Eugonadal Range, Time to Steady State and Drying Time

NCT01228071
View directory record Official record
Conditions
Male Hypogonadism
Interventions
testosterone gel 2%
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
Tucson, Arizona • Middlebury, Connecticut • Oviedo, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 19, 2026, 1:10 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety Evaluating Fispemifene in the Treatment of Hypogonadal Men With Erectile Dysfunction Unresponsive to PDE5 Inhibitors

NCT00415571
View directory record Official record
Conditions
Hypogonadism, Erectile Dysfunction
Interventions
Fispemifene (once daily for 8 weeks)
Drug
Lead sponsor
QuatRx Pharmaceuticals Company
Industry
Eligibility
20 Years and older · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
14
States / cities
Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2010 · Synced Oct 19, 2026, 1:10 PM EDT
Recruiting No phase listed Observational

Registry for Adults With Plasma Cell Disorders (PCD's)

NCT03717844
View directory record Official record
Conditions
Multiple Myeloma, Amyloidosis, Cryoglobulinemia, Castleman's Disease, Light Chain Deposition Disease, Heavy Chain Deposition Disease, Polyneuropathy Organomegaly Endocrinopathy Monoclonal Gammopathy and Skin Changes, Smoldering Multiple Myeloma, Plasma Cell Leukemia
Interventions
Not listed
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Timeline
2018 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 19, 2026, 1:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Risk Factors, Costs, and Impacts of ED Boarding

NCT07532564
View directory record Official record
Conditions
Stroke (CVA) or TIA, Diabetes, Asthma (Diagnosis), COPD (Chronic Obstructive Pulmonary Disease), Sepsis, Hypertension, Heart Failure, Pneumonia, Urinary Tract Infection (Diagnosis), Chest Pain, Psychiatric Disorder, Sickle Cell Disease (SCD)
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
30,486 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 19, 2026, 1:10 PM EDT
Active, not recruiting Phase 2 Interventional

AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC

NCT05632328
View directory record Official record
Conditions
Advanced Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Interventions
AGEN1423, Botensilimab, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
Bruno Bockorny
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 19, 2026, 1:10 PM EDT
Completed Not applicable Interventional Results available

Initiation of Continuous Glucose Monitoring at Diagnosis of Type 1 Diabetes

NCT02734667
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
CGM at diagnosis of T1D
Device
Lead sponsor
Korey Hood
Other
Eligibility
2 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Stanford, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 19, 2026, 1:10 PM EDT
Completed Phase 1 Interventional

Irinotecan and Capecitabine in Treating Patients With Solid Tumors

NCT00003867
View directory record Official record
Conditions
Cancer
Interventions
capecitabine, irinotecan hydrochloride
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 19, 2026, 1:10 PM EDT
Completed Not applicable Interventional

A Continuous Glucose Monitor Based Insulin Bolus Calculator (CGM-IBC) Study B

NCT05343065
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
BlueStar 10
Device
Lead sponsor
Welldoc
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 17, 2023 · Synced Oct 19, 2026, 1:10 PM EDT
Completed Not applicable Interventional Results available

Point-of-Care Glucose Testing and Insulin Supplementation

NCT01702311
View directory record Official record
Conditions
Diabetes
Interventions
Bedtime insulin Aspart (Novolog)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 3, 2018 · Synced Oct 19, 2026, 1:10 PM EDT
Enrolling by invitation No phase listed Observational

Analysis of the Virtual Acute Care at Home Experience

NCT05952999
View directory record Official record
Conditions
Conditions, Infections, Heart Failure, Renal and Urinary Disorders, Diabetes, Hypertension, Fever, Bronchitis, Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Digital Care Solution as supportive personalized care, Traditional Hospital Level Care
Other
Lead sponsor
OSF Healthcare System
Other
Eligibility
18 Years and older
Enrollment
9,654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 19, 2026, 1:10 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of Oral Lipid Ingestion in Relation to Ovarian Androgen Secretion in Polycystic Ovary Syndrome (PCOS)

NCT01489319
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Salsalate
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 19, 2026, 1:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Lifestyle Modification for Type 2 Diabetes Prevention in Overweight Youth

NCT01610219
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Obesity
Interventions
Lifestyle Modification for Type 2 Diabetes Prevention, Nutrition and Physical Activity
Behavioral · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
4 Years to 8 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Oct 19, 2026, 1:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Native Hawaiian Diabetes Intervention Program

NCT00006165
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
'Ohana (Family) Support Lifestyle Intervention
Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
30 Years and older
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 19, 2026, 1:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose

NCT04973111
View directory record Official record
Conditions
Diabetes
Interventions
CT-868 as SC Injection, Placebo as SC Injection, Active Comparator as SC Injection
Drug
Lead sponsor
Carmot Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 19, 2026, 1:10 PM EDT